Search Results

You are looking at 1-10 of 83

Anesthetic Efficacy of Bupivacaine Solutions in Inferior Alveolar Nerve Block
Maria Cristina VolpatoDDS, PhD,
José Ranali DDS, PhD,
Juliana Cama RamacciatoDDS, PhD,
Patrícia Cristine de OliveiraDDS, MS,
Glaúcia Maria Bovi AmbrosanoPhD, and
Francisco Carlos GroppoDDS, PhD
Article Category: Other
Volume/Issue: Volume 52: Issue 4
Online Publication Date: Jan 01, 2005
Page Range: 132 – 135

Racemic bupivacaine has been used as a local anesthetic in medicine and dentistry for many years. The 2 main indications for its use in dentistry are lengthy procedures and management of postoperative pain, as in endodontic, surgical, and periodontal procedures, among others. 1 Although no case of toxicity has been documented in dentistry, a number of authors have reported its potent cardiac toxic effects, even in small doses. 2 Studies that compared racemic bupivacaine and levobupivacaine have shown less toxicity for the latter. 3 , 4 Since 2000, a

Download PDF
Stuart E. LieblichDMD and
Hassan DanesiMD
Article Category: Research Article
Volume/Issue: Volume 64: Issue 3
Online Publication Date: Jan 01, 2017
Page Range: 127 – 135

analgesia is considered one of the most important advancements in dental science during the past century. 21 Infiltration with local anesthetics at the surgical site represents an effective approach to postsurgical analgesia that can be used as part of a multimodal approach to pain management. Local administration minimizes the risk of systemic adverse events (AEs); however, the efficacy of local anesthetics is limited by their short duration of action (typically ≤8–10 hours). 22 Liposomal bupivacaine (EXPAREL, bupivacaine liposome injectable suspension; Pacira

Stuart E. LieblichDMD and
Hassan DanesiMD
Article Category: Other
Volume/Issue: Volume 71: Issue 4
Online Publication Date: Dec 04, 2024
Page Range: 199 – 207

important advancements in dental science during the past century. 21 Infiltration with local anesthetics at the surgical site represents an effective approach to postsurgical analgesia that can be used as part of a multimodal approach to pain management. Local administration minimizes the risk of systemic adverse events (AEs); however, the efficacy of local anesthetics is limited by their short duration of action (typically ≤8–10 hours). 22 Liposomal bupivacaine (EXPAREL, bupivacaine liposome injectable suspension; Pacira Pharmaceuticals, Inc, Parsippany, NJ) is a novel

Figure 2 ; Study population: disposition of subjects. LB indicates liposomal bupivacaine; NRS, numeric rating scale; and ITT, intent-to-treat.
Stuart E. Lieblich and
Hassan Danesi
<bold>Figure 2</bold>
Figure 2

Study population: disposition of subjects. LB indicates liposomal bupivacaine; NRS, numeric rating scale; and ITT, intent-to-treat.


Stuart E. Lieblich and
Hassan Danesi
Figure 2.
Figure 2.

Study population: disposition of subjects LB indicates liposomal bupivacaine; NRS, numeric rating scale; and ITT, intent-to-treat.


Kyle J. KramerDDS, MS
Article Category: Editorial
Volume/Issue: Volume 71: Issue 4
Online Publication Date: Dec 04, 2024
Page Range: 161 – 162

This year’s Landmark Articles in Dental Anesthesiology with Commentary in Honor of Joel M. Weaver, DDS, PhD features a study by Lieblich and Danesi 1 on the analgesic efficacy and safety of liposomal bupivacaine (Exparel, bupivacaine liposome injectable suspension; Pacira Pharmaceuticals, Inc) for patients undergoing extraction of third molars. Used to provide prolonged local anesthetic effects, Exparel features bupivacaine encapsulated in multivesicular liposomes that slowly break down and release bupivacaine over 3 to 4 days. Exparel typically is not

Mana Saraghi and
Elliot V. Hersh
<bold>Figure 3.</bold>
Figure 3.

Diagram of liposomal bupivacaine particle in DepoFoam vehicle. Image supplied courtesy of Pacira Pharmaceuticals Inc.


Karen E. CrowleyMS, DDS and
Mark C. FletcherDMD, MD
Article Category: Other
Volume/Issue: Volume 71: Issue 4
Online Publication Date: Dec 04, 2024
Page Range: 208 – 211

board member and director of the Dental Anesthesia Patient Safety Foundation and his text co-edited with Dr Robert Bosack serves as ample evidence of his passion for patient safety. Published in 2017, Dr Lieblich’s study on the use of liposomal bupivacaine for postoperative analgesia following third molar extractions is a tribute to his substantial interest in and care for others and underscores his commitment to patient safety. The drawbacks of opioid analgesia have had long-term adverse effects in our society as evident by the ongoing opioid epidemic. As surgical